Status
Conditions
Treatments
About
This is a prospective, double-blind, sham-controlled, randomized clinical trial . This study aims to assess the efficacy, safety, tolerability, and the optimal dose of the Mi-Helper transnasal cooling device for acute treatment of migraine in an at home setting.
Adults aged 18 years to 65 years old with a diagnosis of episodic migraine (with or without aura) for at least one year (self-reported) will be recruited for this study.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
172 participants in 4 patient groups
Loading...
Central trial contact
Joy Holland; Casey Hannan
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal